⌘K
t
Synairgen plc announced the results of its Annual General Meeting held on June 30, 2022. All resolutions proposed at the AGM were passed. Resolutions 12 (to authorise the directors to allot shares) and 13 (to disapply pre-emption rights) were withdrawn from the agenda following discussions with a small number of shareholders.
| Date | 30 Jun 2022 |
| Time | 13:45:04 |
| Category | AGMs and other meetings |
| ID | 8673Q |
Annual Report and Accounts (to 2021-12-31)
Synairgen plc
('Synairgen' or the 'Company')
Results of Annual General Meeting
Southampton, UK - 30 June 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces the results of voting at its Annual General Meeting today. All resolutions proposed at its Annual General Meeting were passed.
Resolutions 12 (to authorise the directors to allot shares) and 13 (to disapply pre-emption rights) were withdrawn from the agenda following discussions with a small number of shareholders.
The full results of the proxy voting and text of the resolutions can be viewed by visiting the Company's website at www.Synairgen.com.
For further enquiries, please contact:
Synairgen plc
Brooke Clarke, Head of Communications
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott, Namrata Taak, Lucy Featherstone
Tel: +44 (0) 20 3709 5700
MKC STRATEGIES, LLC (US Media Relations)
Mary Conway
Tel: +1 516-606-6545
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of severe viral lung infections, including COVID-19, as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA). Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com.